IDH2 and glioma: However, gain-of-function mutations in IDH1 or IDH2 convert α-KG into D-2-HG, leading to its pathological accumulation in various cancers such as acute myeloid leukemia (AML), glioma, chondrosarcoma, and cholangiocarcinoma [11, 12].